Found: 12
Select item for more details and to access through your institution.
Efficacy and safety of evolocumab in individuals with type 2 diabetes mellitus: primary results of the randomised controlled BANTING study.
- Published in:
- Diabetologia, 2019, v. 62, n. 6, p. 948, doi. 10.1007/s00125-019-4856-7
- By:
- Publication type:
- Article
Randomized study of evolocumab in patients with type 2 diabetes and dyslipidaemia on background statin: Pre‐specified analysis of the Chinese population from the BERSON clinical trial.
- Published in:
- Diabetes, Obesity & Metabolism, 2019, v. 21, n. 6, p. 1464, doi. 10.1111/dom.13700
- By:
- Publication type:
- Article
Randomised study of evolocumab in patients with type 2 diabetes and dyslipidaemia on background statin: Primary results of the BERSON clinical trial.
- Published in:
- Diabetes, Obesity & Metabolism, 2019, v. 21, n. 6, p. 1455, doi. 10.1111/dom.13680
- By:
- Publication type:
- Article
Evaluation of the efficacy, safety and glycaemic effects of evolocumab ( AMG 145) in hypercholesterolaemic patients stratified by glycaemic status and metabolic syndrome.
- Published in:
- Diabetes, Obesity & Metabolism, 2017, v. 19, n. 1, p. 98, doi. 10.1111/dom.12788
- By:
- Publication type:
- Article
Effects of evolocumab in individuals with type 2 diabetes with and without atherogenic dyslipidemia: An analysis from BANTING and BERSON.
- Published in:
- Cardiovascular Diabetology, 2021, v. 20, n. 1, p. 1, doi. 10.1186/s12933-021-01287-6
- By:
- Publication type:
- Article
Effects of evolocumab in individuals with type 2 diabetes with and without atherogenic dyslipidemia: An analysis from BANTING and BERSON.
- Published in:
- Cardiovascular Diabetology, 2021, v. 20, n. 1, p. 1, doi. 10.1186/s12933-021-01287-6
- By:
- Publication type:
- Article
Rationale and design of a randomized study to assess the efficacy and safety of evolocumab in patients with diabetes and dyslipidemia: The BERSON clinical trial.
- Published in:
- Clinical Cardiology, 2018, v. 41, n. 9, p. 1117, doi. 10.1002/clc.23018
- By:
- Publication type:
- Article
Quantification of LDL-Cholesterol Corrected for Molar Concentration of Lipoprotein(a).
- Published in:
- Cardiovascular Drugs & Therapy, 2024, v. 38, n. 1, p. 191, doi. 10.1007/s10557-022-07407-y
- By:
- Publication type:
- Article
Efficacy and Safety of Evolocumab in Chinese Patients with Primary Hypercholesterolemia and Mixed Dyslipidemia: 12-Week Primary Results of the HUA TUO 华佗 Randomized Clinical Trial.
- Published in:
- Cardiology & Therapy, 2023, v. 12, n. 2, p. 341, doi. 10.1007/s40119-023-00304-x
- By:
- Publication type:
- Article
A Phase 1, Randomized, Double-Blind, Single-Dose, Placebo-Controlled Safety, Tolerability, And Pharmacokinetic/Pharmacodynamic Study Of Evolocumab In Healthy Chinese Subjects.
- Published in:
- Clinical Pharmacology, 2019, v. 11, p. 145, doi. 10.2147/CPAA.S208033
- By:
- Publication type:
- Article
Effects of Evolocumab on Low-Density Lipoprotein Cholesterol, Non-High Density Lipoprotein Cholesterol, Apolipoprotein B, and Lipoprotein(a) by Race and Ethnicity: A Meta-Analysis of Individual Participant Data From Double-Blind and Open-Label Extension Studies.
- Published in:
- 2021
- By:
- Publication type:
- journal article
Effect of Evolocumab on Non-High-Density Lipoprotein Cholesterol, Apolipoprotein B, and Lipoprotein(a): A Pooled Analysis of Phase 2 and Phase 3 Studies.
- Published in:
- 2020
- By:
- Publication type:
- journal article